Director Clinical DevelopmentCSL Behring, Marburg, GermanyMarburg, Hessen, Germany
PB0650 - Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Pediatric Patients with Hemophilia B: A review of results from Phase 3 trial studies
Monday, June 26, 202318:30 – 19:30 ET
PB0692 - Matching-adjusted indirect comparison of rIX-FP versus rFIXFc for prophylactic treatment of hemophilia B
